跳至主要内容
临床试验/CTRI/2022/09/045312
CTRI/2022/09/045312已完成未知

Comparison of safety and efficacy of 2 brands of Botulinum Toxin A for the treatment of crow’s feet: A Split face study

Gufic Biosciences Ltd0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 18 years and above
  • Both Male and Female
  • Moderate to severe lateral canthal lines associated with orbicularis oculi activity

排除标准

  • a)Known Hypersensitivity to Botulinum Toxin
  • b)Subjects with neuromuscular disorders (myasthenia gravis, Lambert-Eaton myasthenic syndrome, amyotrophic lateral sclerosis, or motor neuropathy)
  • c)Subjects who used medications that interfere with the neuromuscular function, such as aminoglycoside antibiotics and curare-like agents, within 4 weeks before screening.
  • d)Subjects with a previous injection of botulinum toxin Type A within 3 months or cosmetic procedures associated with crow’s feet
  • e)Pregnancy and lactation

研究者

相似试验

To study the safety and efficacy of Botulinum toxin... | 临床试验